Case Study: Immunomedics (biopharmaceutical company) achieves streamlined equity management and tighter reporting with Carta (equity management platform)

Immunomedics manages their equity through key milestones on Carta

Immunomedics, a commercial biopharmaceutical company that develops antibody-based cancer treatments, was struggling with a manual, paper-based equity process as it transitioned from R&D to an FDA‑approved company following $459M in funding and approval of Trodelvy. They needed better accounting, security, user experience, and searchable online records to manage employee equity and performance grants, so they turned to Carta’s equity management platform.

Carta implemented its platform and dedicated support to migrate Immunomedics off months‑behind paperwork into real‑time online records, customizable reporting, and employee training resources. The change produced tighter, auditor‑trusted reporting, enabled handling of high volumes of post‑approval transactions, improved stakeholder experience, and prompted the company to expand additional Carta services.

Immunomedics

David Clark

Director